PitchBook clients can access the full report via the Research Center on the PitchBook Platform.
Pharma biotools approaches record year as VC investors flock to early-stage technologies
The pharma biotools sector—which encompasses technologies and services for drug discovery, clinical development, biopharmaceutical manufacturing, and diagnostics—is on pace for 513 VC deals in 2025, which is well above the previous annual record of 442. The sector has evolved from capital-intensive hardware providers to sophisticated platforms integrating digital technologies into wet-lab approaches. The new ability to operate software-as-a-service-like business models has led to the proliferation of early-stage startups, and investors are following. Seed-stage startups have accounted for a record 18% of total capital deployed YTD, as investment is heavily weighted toward emerging technologies rather than mature startups.
AI integration into biotech has been a major driver of this uptick as computational tools and emerging biological foundation models continue to attract significant capital. Lila Sciences, pursuing “scientific superintelligence” through autonomous labs, raised a $350 million Series A at a $1.3 billion valuation. Chai Discovery raised $70 million at a $573 million valuation for its de novo antibody design model. Other notable deals and areas of investment in Q3 included the synthetic biology & CRISPR category, headlined by Colossal Biosciences’ $120 million Series C extension.